
Tenaya Therapeutic (TNYA) Stock Forecast & Price Target
Tenaya Therapeutic (TNYA) Analyst Ratings
Bulls say
Tenaya Therapeutics Inc. is progressing with its gene therapy programs, having received positive safety reviews from independent Data Safety and Monitoring Boards (DSMB) to advance its clinical trials, including the Phase 1b/2 MyPEAK-1 trial and the Phase 1b RIDGE-1 trial. The company's commitment to developing therapies for heart disease is underscored by its successful enrollment of patients in critical trial cohorts, indicating strong operational momentum and patient engagement. Furthermore, initial modeling linked Left Ventricular Mass Index (LVMI) with significant predictive risk, highlighting the potential for Tenaya’s therapies to address critical health markers in cardiovascular diseases.
Bears say
Tenaya Therapeutics faces a negative outlook largely due to potential setbacks in its clinical trials, which can result in failed or inconclusive results that could adversely impact the company's future. Furthermore, there is significant concern regarding the company's ability to secure sufficient funding to progress its drug development, which is critical for a preclinical-stage biotechnology firm. Lastly, the risk of dilutive capital raises adds to the uncertainty surrounding its financial stability and growth prospects.
This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.
Tenaya Therapeutic (TNYA) Analyst Forecast & Price Prediction
Start investing in Tenaya Therapeutic (TNYA)
Order type
Buy in
Order amount
Est. shares
0 shares